Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Oncopeptides AB. (1/19/17). "Press Release: First Patients Are Now Enrolled in HORIZON, Oncopeptides’ Phase II Clinical Trial in Late Stage Relapsed and Refractory Multiple Myeloma".

Organisation Organisation Oncopeptides AB (Nasdaq Stockholm: ONCO)
  Group Oncopeptides (Group)
Products Product Ygalo
  Product 2 clinical research
Person Person Lindberg, Jakob (Oncopeptides AB 202102 CSO before CEO)

Oncopeptides AB, a clinical stage pharmaceutical company, developing the peptidase potentiated therapy Ygalo (melflufen), announced that the clinical development program is continuing according to plan. The company has recently initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The clinical trial is conducted in patients with late stage relapsed and refractory multiple myeloma (RRMM) that are refractory to treatments with pomalidomide and/or daratumumab.

“This is an important step in our strategy to develop Ygalo to become the first targeted alkylator for treating multiple myeloma patients with limited remaining treatment options” said Jakob Lindberg, CEO Oncopeptides.

The clinical study will be conducted across 15 clinics in Italy, Spain and the US, with Dana Farber Cancer Institute in Boston, MA, being the lead investigator site. The study will recruit patients that have become refractory to pomalidomide and/or daratumumab, currently the two main treatment alternatives in patients with late stage relapsed and refractory multiple myeloma.

Multiple myeloma is a rare form of hematological cancer. In 2016, it is estimated that there will be 30,300 new cases of multiple myeloma in the US and an estimated 12,650 patients will die of the disease in the US alone[1]. The five-year survival rate is currently 48.5%.[1]

For further information, contact

Jakob Lindberg, CEO
Oncopeptides AB, Stockholm, Sweden
Tel.: +46 (0)705 695 471

About Oncopeptides

Oncopeptides is a research-based pharmaceutical company based in Stockholm, Sweden. The Company’s product candidate Ygalo is based on the active compound melflufen.

Ygalo is intended for the treatment of patients with multiple myeloma, a blood cancer disease that currently has no cure. Oncopeptides is currently in late stage of its clinical development programs.

For more information, visit:

[1] National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Accessed June 07, 2016.

Record changed: 2017-01-26


Picture [iito] Plain Stupid Simple 650x80px

More documents for Oncopeptides (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top